BioPharma Dive – AI / Data
J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J&J has said the new drug, Icotyde, has the potential to top $5 billion in sales.